
AngioGenex, Inc. (Ticker: AGGX) announced an exclusive agreement with Memorial Sloan Kettering Cancer Center (MSK) to license and advance a series of anti-ID compounds through the regulatory process and into human clinical…
AngioGenexFebruary 13, 2020